+ 4.25
+ 1.17%
+ 2.33
+ 0.67%
+ 4.31
+ 0.99%

Amazon Could Partner With UnitedHealth For Pharmacy Unit By Thanksgiving

October 9, 2017 12:12 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Last week, Leerink analyst David Larsen said that it’s only a matter of time before Amazon.com, Inc. (NASDAQ:AMZN) takes the plunge into the pharmacy business and that Amazon could be selling prescription drugs within two years’ time. On Monday, Bernstein analyst Lance Wilkes said Amazon investors may not need to wait two years.

According to Wilkes, Amazon will likely make its pharmacy intentions official and public before Thanksgiving. Rather than build its own pharmacy benefit manager business from scratch, Wilkes said he expects Amazon to go the Whole Foods route and either buy or partner with an existing PBM.

“Over the past five months we have stated that we think Amazon will enter the retail pharmacy industry, we think they will most likely partner/buy a PBM to enable their entry, and we think they will address the major challenges which have faced online (mail) pharmacy, which are user experience, convenience and price,” Wilkes wrote.

Bernstein sees a partnership with UnitedHealth Group Inc (NYSE:UNH)’s OptumRx as the path that makes the most sense for Amazon. However, Amazon could also still choose to buy a mail-order pharmacy business or take over a mid-sized independent PBM. Wilkes specifically noted that he does not see Express Scripts Holding Company (NASDAQ:ESRX) as a likely buyout target for Amazon.

Bernstein is expecting Amazon to have its pharmacy business up and running in 2019 and in time for 2020 benefit plans. Not only would Amazon’s presence threaten the market share of all the major drug retailers and PBM’s, including Walgreens Boots Alliance Inc (NASDAQ:WBA) and CVS Health Corp (NYSE:CVS), Wilkes said it could pressure margins across the board, including those of a potential partner.

Bernstein has an Outperform rating and $210 price target for UnitedHealth.

Related Link: Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Related Articles

Why This Amazon Analyst Sees Risk To Short-Term Revenue Guidance

Amazon, Inc. (NASDAQ: AMZN) shares had a lukewarm showing in the first half of the year, but have since picked up steam. read more

How FAANGs Could Benefit From Chinese Regulatory Scrutiny Of Domestic Tech Stocks

Chinese regulators have started to tighten the leash on high-flying Chinese tech stalwarts such as Tencent Holdings Limited (OTC: TCEHY), Alibaba Group Holding Limited (NYSE: BABA), Baidu, Inc. read more

Cantor Fitzgerald Has Some Suggestions On How Schumer's Federal Marijuana Legalization Bill Can Achieve Sufficient Senate Approval For Passage

Details of the Cannabis Administration and Opportunity Act (CAOA) draft bill, were released last Wednesday morning. read more

Apple May Be Trailing Google, Facebook In YTD Gains By Far But Munster Still Expects It To Be Top-Performing FAANG Stock In Rest Of 2021

Despite Apple Inc’s (NASDAQ: AAPL) distant fourth rank among FAANG peers in terms of first-half gains, Loup Ventures analyst Gene Munster is bullish the Cupertino-based company will emerge as the top performer through the rest of 2021. read more